Human CD4+ and CD8+ T cells were isolated from the PBMCs of patients with RRMS and healthy donors by immunomagnetic separation using CD4+ or CD8+-labelled magnetic-activated cell sorting (MACS) microbeads (Miltenyi Biotec), respectively. For the purification of the T-cell subsets [memory (TM) and naïve (TN)], CD4+ or CD8+ T cells were enriched using a negative selection technique (Miltenyi Biotec) and subsequently TM cells (CD45RO+) and TN cells (CD45RO) were isolated using CD45RO+-labelled MACS microbeads. All T cells were cultured in X-VIVOTM Media 15 (Lonza). When indicated, 5 µg/ml DMF, 5 µg/ml monomethyl fumarate, 250 nM N-acetylcysteine (NAC), 250 µM glutathione (all from Merck) and 100 µM mitoquinone mesylate (MitoQ; MedChem Express) were used. Sulphoraphane (500 nM, Merck) was applied for pharmacological activation of Nrf2.23 (link) For pharmacological inhibition of Nrf2, 5 µg/ml ML385 (Merck) was used.24 (link) Buthionine sulphoximine (3 mM, Merck) was utilized as a specific inhibitor of glutamate cysteine ligase, the rate-limiting step in glutathione synthesis.25 (link) For a detailed description see the Supplementary material.